COVID-19 Vaccines’ Protection Over Time and the Need for Booster Doses; a Systematic Review
学术急诊医学档案,
卷 10 编号 1 (2022),
1 一月 2022
,
第 e53 页
https://doi.org/10.22037/aaem.v10i1.1582
摘要
Introduction: Controversies existed regarding the duration of COVID-19 vaccines’ protection and whether receiving the usual vaccine doses would be sufficient for long-term immunity. Therefore, we aimed to systematically review the studies regarding the COVID-19 vaccines’ protection three months after getting fully vaccinated and assess the need for vaccine booster doses.
Methods: The relevant literature was searched using a combination of keywords on the online databases of PubMed, Scopus, Web of Science, and Cochrane on September 17th, 2021. The records were downloaded and the duplicates were removed. Then, the records were evaluated in a two-step process, consisting of title/abstract and full-text screening processes, and the eligible records were selected for the qualitative synthesis. We only included original studies that evaluated the efficacy and immunity of COVID-19 vaccines three months after full vaccination. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement to ensure the reliability of results.
Results: Out of the 797 retrieved records, 12 studies were included, 10 on mRNA-based vaccines and two on inactivated vaccines. The majority of included studies observed acceptable antibody titers in most of the participants even after 6 months; however,it appeared that the titers could also decrease in a considerable portion of people. Due to the reduction in antibody titers and vaccine protection, several studies suggested administering the booster dose, especially for older patients and those with underlying conditions, such as patients with immunodeficiencies.
Conclusion: Studies indicated that vaccine immunity decreases over time, making people more susceptible to contracting the disease. Besides, new variants are emerging, and the omicron variant is continuing to spread and escape from the immune system, indicating the importance of a booster dose.
- COVID-19
- COVID-19 vaccines
- Immunity
- SARS-CoV-2
- Vaccines
- Vaccine-preventable diseases
##submission.howToCite##
参考
WHO Coronavirus (COVID-19) Dashboard [Available from: https://covid19.who.int/.
Mehraeen E, Oliaei S, SeyedAlinaghi S, Karimi A, Mirzapour P, Afsahi AM, et al. COVID-19 in Pediatrics: A Systematic Review of Current Knowledge and Practice. Infect Disord Drug Targets. 2022; 22(5): e290921196908.
Mehraeen E, SeyedAlinaghi S, Karimi A. Can children of the Sputnik V vaccine recipients become symptomatic? Human vaccines & immunotherapeutics. 2021;17(10):3500-1.
Mehraeen E, Dadras O, Afsahi AM, Karimi A, Pour MM, Mirzapour P, et al. Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. Infect Disord Drug Targets. 2022;22(2):e230921196758.
Sheikhbahaei E, Mirghaderi SP, Moharrami A, Habibi D, Motififard M, Mortazavi SMJ. Incidence of Symptomatic COVID-19 in Unvaccinated Patients Within One Month After Elective Total Joint Arthroplasty: A Multicenter Study. Arthroplast Today. 2022;14:110-5.
Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet (London, England). 2021;398(10309):1407-16.
Glück V, Grobecker S, Köstler J, Tydykov L, Bertok M, Weidlich T, et al. Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel. Infection. 2022;50(2):439-46.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Gurevich M. Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose? Eur J Intern Med. 2021;94:105-7.
Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-73.
FDA. Vaccines and Related Biological Products Advisory Committee Briefing Document - US Food and Drug Administration 2021 [Available from: https://www.fda.gov/media/152161/download.
Fast HE, Zell E, Murthy BP, Murthy N, Meng L, Scharf LG, et al. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years - United States, August 13, 2021-November 19, 2021. MMWR Morbidity and mortality weekly report. 2021;70(50):1735-9.
Juno JA, Wheatley AK. Boosting immunity to COVID-19 vaccines. Nature medicine. 2021;27(11):1874-5.
Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595(7867):426-31.
Kiefer MK, Allen KD, Russo JR, Ma'ayeh M, Gee SE, Kniss D, et al. Decline in Sars-CoV-2 antibodies over 6-month follow-up in obstetrical healthcare workers. Am J Reprod Immunol. 2021;86(6):e13490.
Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J Infect. 2021;82(5):162-9.
Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208.
Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A, Horeanga A, et al. Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary. J Infect. 2021;83(5):559-64.
Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S, Apostolakou F, et al. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021;10(8):1942.
Erice A, Varillas-Delgado D, Caballero C. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. Clin Microbiol Infect. 2022;28(1):139.e1-.e4.
Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerging microbes & infections. 2021;10(1):1495-8.
Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine. 2021;38:101010.
Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A, et al. Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. Cancer discovery. 2021.
Mohapatra RK, Tiwari R, Sarangi AK, Islam MR, Chakraborty C, Dhama K. Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates. J Med Virol. 2022;94(6):2336-42.
Hedges JF, Thompson MA, Snyder DT, Robison A, Taylor MP, Jutila MA. Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination. Vaccines (Basel). 2021;9(6):587.
Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, et al. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine. 2021;39:101078.
Pouquet M, Decarreaux D, Prévot-Monsacré P, Hervé C, Werner A, Grosgogeat B, et al. Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol. Pathogens. 2021;10(7):911.
Vicenti I, Basso M, Gatti F, Scaggiante R, Boccuto A, Zago D, et al. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. Int J Infect Dis. 2021;112:40-4.
- 摘要 ##plugins.themes.ojsPlusA.frontend.article.viewed##: 1255 ##plugins.themes.ojsPlusA.frontend.article.times##
- pdf (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 570 ##plugins.themes.ojsPlusA.frontend.article.times##
##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##
##plugins.block.makeSubmission.linkLabel##
SJR
COPE
